Abstract
Synaptic dysfunction is involved in early stages of Alzheimers disease (AD). Amyloid-β peptides (Aβ), a neuropathologic hallmark of the disease, have been shown to alter synaptic function. Given that Aβ is present in different forms including monomeric, oligomeric and fibrillar species, we have investigated whether fibrillar Aβ impairs synaptic function. Here we report that a synthetic fibrillar form of Aβ impairs the late protein-synthesis dependent phase of LTP without affecting the early protein-synthesis independent phase. These findings add to previous reports that Aβ oligomers are highly toxic to cells and might cause synaptic dysfunction, and suggest that a therapeutic intervention in AD should include the use of drugs inhibiting and disassembling fibril formation in addition to drugs inhibiting oligomers formation.
Keywords: Synapse, amyloid, Alzheimer's disease, synaptic plasticity, fibrils
Current Alzheimer Research
Title: Fibrillar β-Amyloid Impairs the Late Phase of Long Term Potentiation
Volume: 3 Issue: 3
Author(s): Daniela Puzzo and Ottavio Arancio
Affiliation:
Keywords: Synapse, amyloid, Alzheimer's disease, synaptic plasticity, fibrils
Abstract: Synaptic dysfunction is involved in early stages of Alzheimers disease (AD). Amyloid-β peptides (Aβ), a neuropathologic hallmark of the disease, have been shown to alter synaptic function. Given that Aβ is present in different forms including monomeric, oligomeric and fibrillar species, we have investigated whether fibrillar Aβ impairs synaptic function. Here we report that a synthetic fibrillar form of Aβ impairs the late protein-synthesis dependent phase of LTP without affecting the early protein-synthesis independent phase. These findings add to previous reports that Aβ oligomers are highly toxic to cells and might cause synaptic dysfunction, and suggest that a therapeutic intervention in AD should include the use of drugs inhibiting and disassembling fibril formation in addition to drugs inhibiting oligomers formation.
Export Options
About this article
Cite this article as:
Puzzo Daniela and Arancio Ottavio, Fibrillar β-Amyloid Impairs the Late Phase of Long Term Potentiation, Current Alzheimer Research 2006; 3 (3) . https://dx.doi.org/10.2174/156720506777632871
DOI https://dx.doi.org/10.2174/156720506777632871 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Host Neuro- Immuno-Endocrine Responses In Periodontal Disease
Current Pharmaceutical Design Commentary Research Highlights: Untangling Alzheimer Disease Pathology
CNS & Neurological Disorders - Drug Targets Nanoparticles as Alternative Strategies for Drug Delivery to the Alzheimer Brain: Electron Microscopy Ultrastructural Analysis
CNS & Neurological Disorders - Drug Targets Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Age-Dependent Biochemical Dysfunction in Skeletal Muscle of Triple- Transgenic Mouse Model of Alzheimer`s Disease
Current Alzheimer Research Meet Our Editorial Board Member
Current Alzheimer Research Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews Recent Advances in Progressive Supranuclear Palsy: A Review
Current Alzheimer Research Pharmacological Treatment of Hypertension in Pregnancy
Current Pharmaceutical Design Inflammation as Therapeutic Objective in Stroke
Current Pharmaceutical Design Is Nitric Oxide Assuming a Janus-Face in The Central Nervous System?
Current Medicinal Chemistry Assessment and Imaging of the Cerebrovascular Glycocalyx
Current Neurovascular Research Regulation of Innate Immune Responses in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Recent Developments in PET Instrumentation
Current Pharmaceutical Biotechnology The Detection of Adverse Events in Randomized Clinical Trials: Can we Really Say New Medicines are Safe?
Current Drug Safety Impact of Anabolic Androgenic Steroids on Neuropeptide Systems
Mini-Reviews in Medicinal Chemistry Clinical Significance of Pleiotropic Effects of Statins: Lipid Reduction and Beyond
Current Medicinal Chemistry Ajmalicine and its Analogues Against AChE and BuChE for the Management of Alzheimer’s Disease: An <i>In-silico</i> Study
Current Pharmaceutical Design Plasma Steroid Level Measured Using Modern Separation Techniques as Biomarkers in Biological Diagnostics
Current Pharmaceutical Analysis Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design